Back to search

France· FR:65429862

OMJJARA 200 mg, comprimé pelliculé

A momelotinib product containing dichlorhydrate de momélotinib, registered in France by GLAXOSMITHKLINE TRADING SERVICES (IRLANDE), on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC L01EJ04

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedOMJJARA 200 mg, comprimé pelliculéATCL01EJ04REGISTER NO.FR:65429862PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Momelotinib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose

Momelotinib · ATC L01EJ04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of momelotinib costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.

  • France: $0.16 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Momelotinib · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$309.44
  • FR France$0.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
DICHLORHYDRATE DE MOMÉLOTINIB
Manufacturer
GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
Country
France (FR)
ATC code
L01EJ04
ATC class
Momelotinib
Defined daily dose
0.2 g, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930282748
    flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimé(s)
    EUR 3.17

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/71bfd1a3-6f1f-4b90-9db6-c0819a568655
GET /v1/drugs/71bfd1a3-6f1f-4b90-9db6-c0819a568655?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "65429862",
  "date_amm": "2024-01-25",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/23/1782",
  "substance": "DICHLORHYDRATE DE MOMÉLOTINIB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "comprimé pelliculé",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

See everything about momelotinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.